Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 12 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 500288 | NSE: MOREPENLAB

Morepen Laboratories Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 8, 2025, 11:19 am

Market Cap 2,722 Cr.
Current Price 49.7
High / Low 101/38.6
Stock P/E21.6
Book Value 20.3
Dividend Yield0.00 %
ROCE16.8 %
ROE12.0 %
Face Value 2.00
PEG Ratio10.57

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Morepen Laboratories Ltd

Competitors of Morepen Laboratories Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
MPS Pharmaa Ltd 6.71 Cr. 3.51 4.33/3.05 0.800.00 %9.15 %34.9 % 10.0
Gujarat Themis Biosyn Ltd 2,663 Cr. 244 390/19250.6 20.50.27 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 53.1 Cr. 71.5 94.9/32.118.0 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 38.0 Cr. 26.0 29.0/8.7438.8 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 70.4 Cr. 93.5 155/79.011.4 55.40.00 %14.4 %15.5 % 10.0
Industry Average17,255.37 Cr1,081.8442.42185.800.37%16.00%16.32%6.27

All Competitor Stocks of Morepen Laboratories Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 396368302403348364401422445423455438453
Expenses 364350288374328348375388394375404394417
Operating Profit 32191529211626345148524436
OPM % 8%5%5%7%6%4%7%8%11%11%11%10%8%
Other Income 3311132344355
Interest 1100110021111
Depreciation 77777788810624
Profit before tax 2714822141121294442484635
Tax % 21%13%32%29%36%26%29%26%27%32%25%24%24%
Net Profit 22126169815213229363527
EPS in Rs 0.480.260.110.310.180.160.290.420.630.550.710.640.49

Last Updated: February 28, 2025, 6:21 pm

Below is a detailed analysis of the quarterly data for Morepen Laboratories Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹453.00 Cr.. The value appears strong and on an upward trend. It has increased from 438.00 Cr. (Sep 2024) to ₹453.00 Cr., marking an increase of ₹15.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹417.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 394.00 Cr. (Sep 2024) to ₹417.00 Cr., marking an increase of ₹23.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹36.00 Cr.. The value appears to be declining and may need further review. It has decreased from 44.00 Cr. (Sep 2024) to ₹36.00 Cr., marking a decrease of 8.00 Cr..
  • For OPM %, as of Dec 2024, the value is 8.00%. The value appears to be declining and may need further review. It has decreased from 10.00% (Sep 2024) to 8.00%, marking a decrease of 2.00%.
  • For Other Income, as of Dec 2024, the value is ₹5.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 5.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹1.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 1.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹4.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Sep 2024) to ₹4.00 Cr., marking an increase of ₹2.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹35.00 Cr.. The value appears to be declining and may need further review. It has decreased from 46.00 Cr. (Sep 2024) to ₹35.00 Cr., marking a decrease of 11.00 Cr..
  • For Tax %, as of Dec 2024, the value is 24.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 24.00%.
  • For Net Profit, as of Dec 2024, the value is ₹27.00 Cr.. The value appears to be declining and may need further review. It has decreased from 35.00 Cr. (Sep 2024) to ₹27.00 Cr., marking a decrease of 8.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 0.49. The value appears to be declining and may need further review. It has decreased from ₹0.64 (Sep 2024) to 0.49, marking a decrease of ₹0.15.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 3:28 pm

MetricMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 3263674014855956077698531,1881,5471,4181,6901,769
Expenses 2953183524245345427017851,0701,4101,3381,5321,589
Operating Profit 314948626165686911913780159180
OPM % 10%13%12%13%10%11%9%8%10%9%6%9%10%
Other Income 641-34449121061418
Interest 121091084222-7244
Depreciation 46463935343440373028283322
Profit before tax -21-3213243029399912756135172
Tax % 0%0%6%-1%0%0%1%14%1%20%31%29%
Net Profit -21-321324302934971023997126
EPS in Rs -0.46-0.060.050.280.530.660.640.752.162.130.761.882.39
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)85.71%166.67%550.00%84.62%25.00%-3.33%17.24%185.29%5.15%-61.76%148.72%
Change in YoY Net Profit Growth (%)0.00%80.95%383.33%-465.38%-59.62%-28.33%20.57%168.05%-180.14%-66.92%210.48%

Morepen Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:17%
5 Years:17%
3 Years:12%
TTM:8%
Compounded Profit Growth
10 Years:34%
5 Years:27%
3 Years:0%
TTM:66%
Stock Price CAGR
10 Years:14%
5 Years:34%
3 Years:3%
1 Year:5%
Return on Equity
10 Years:13%
5 Years:14%
3 Years:12%
Last Year:12%

Last Updated: Unknown

Balance Sheet

Last Updated: December 14, 2024, 3:08 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 90909090909090909096102102110
Reserves 908878911061361631943354836517451,001
Borrowings 2312092011871691341321331719252933
Other Liabilities 95103121156173226230246416473332417418
Total Liabilities 5064904895245385866156638581,0701,1101,2931,562
Fixed Assets 409368322297272264236216225252267307355
CWIP 00000000214172418
Investments 400000011001132
Other Assets 931211672272663213794466318048279601,056
Total Assets 5064904895245385866156638581,0701,1101,2931,562

Below is a detailed analysis of the balance sheet data for Morepen Laboratories Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹110.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹102.00 Cr. (Mar 2024) to ₹110.00 Cr., marking an increase of 8.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹1,001.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹745.00 Cr. (Mar 2024) to ₹1,001.00 Cr., marking an increase of 256.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹33.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from ₹29.00 Cr. (Mar 2024) to ₹33.00 Cr., marking an increase of 4.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹418.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹417.00 Cr. (Mar 2024) to ₹418.00 Cr., marking an increase of 1.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹1,562.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹1,293.00 Cr. (Mar 2024) to ₹1,562.00 Cr., marking an increase of 269.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹355.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹307.00 Cr. (Mar 2024) to ₹355.00 Cr., marking an increase of 48.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹18.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹24.00 Cr. (Mar 2024) to ₹18.00 Cr., marking a decrease of 6.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹132.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1.00 Cr. (Mar 2024) to ₹132.00 Cr., marking an increase of 131.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹1,056.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹960.00 Cr. (Mar 2024) to ₹1,056.00 Cr., marking an increase of 96.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹1,562.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,293.00 Cr. (Mar 2024) to ₹1,562.00 Cr., marking an increase of 269.00 Cr..

Notably, the Reserves (₹1,001.00 Cr.) exceed the Borrowings (33.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-200.00-160.00-153.00-125.00-108.00-69.00-64.00-64.00102.00118.0055.00130.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days444251665773645956596870
Inventory Days685655516576699182968785
Days Payable104116126140125173124113989087101
Cash Conversion Cycle8-17-20-23-3-2493740656954
Working Capital Days-19-20-18-10-86-62-30-3225910499
ROCE %-3%1%3%8%9%9%8%10%25%25%9%17%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters38.38%36.74%38.22%38.22%38.22%38.22%38.22%38.22%38.22%38.22%35.66%35.66%
FIIs0.96%0.95%1.15%0.89%0.96%1.00%1.29%2.11%1.85%1.67%2.08%2.22%
DIIs1.07%4.08%3.98%3.74%2.93%2.32%2.27%2.21%2.15%2.14%1.69%1.64%
Government0.00%0.00%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%
Public59.59%58.24%56.63%57.15%57.88%58.45%58.20%57.46%57.76%57.96%60.57%60.46%
No. of Shareholders2,61,4372,87,1152,90,3673,06,0303,06,1503,01,8323,04,0013,04,2893,36,0193,48,7664,30,9294,48,361

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Motilal Oswal BSE Healthcare ETF4,4010.160.024,4012025-03-060%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 2.002.002.002.002.00
Basic EPS (Rs.) 1.880.772.262.160.75
Diluted EPS (Rs.) 1.880.771.962.160.75
Cash EPS (Rs.) 2.541.302.712.831.57
Book Value[Excl.RevalReserv]/Share (Rs.) 16.5814.7212.109.436.30
Book Value[Incl.RevalReserv]/Share (Rs.) 16.5814.7212.109.436.30
Revenue From Operations / Share (Rs.) 33.0727.7332.3726.4118.97
PBDIT / Share (Rs.) 3.381.683.082.901.73
PBIT / Share (Rs.) 2.721.132.502.230.91
PBT / Share (Rs.) 2.651.092.652.190.86
Net Profit / Share (Rs.) 1.890.752.132.160.74
NP After MI And SOA / Share (Rs.) 1.880.752.132.160.74
PBDIT Margin (%) 10.216.049.5010.999.14
PBIT Margin (%) 8.234.077.718.444.81
PBT Margin (%) 8.013.938.198.294.58
Net Profit Margin (%) 5.712.726.578.173.93
NP After MI And SOA Margin (%) 5.682.726.578.173.93
Return on Networth / Equity (%) 11.345.1317.5722.8511.82
Return on Capital Employeed (%) 15.617.3119.4422.0713.16
Return On Assets (%) 7.433.489.5011.315.06
Total Debt / Equity (X) 0.030.030.030.030.04
Asset Turnover Ratio (%) 1.411.301.601.471.24
Current Ratio (X) 2.212.351.611.301.06
Quick Ratio (X) 1.591.641.000.870.66
Inventory Turnover Ratio (X) 3.703.103.534.013.65
Interest Coverage Ratio (X) 46.5243.25-19.9673.0239.30
Interest Coverage Ratio (Post Tax) (X) 27.0420.53-12.8155.2917.92
Enterprise Value (Cr.) 2126.721280.991720.861393.88402.04
EV / Net Operating Revenue (X) 1.260.901.111.170.47
EV / EBITDA (X) 12.3214.9511.7110.675.15
MarketCap / Net Operating Revenue (X) 1.270.921.131.220.50
Price / BV (X) 2.541.743.023.401.51
Price / Net Operating Revenue (X) 1.270.921.131.220.50
EarningsYield 0.040.020.050.060.07

After reviewing the key financial ratios for Morepen Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 1.88. This value is below the healthy minimum of 5. It has increased from 0.77 (Mar 23) to 1.88, marking an increase of 1.11.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 1.88. This value is below the healthy minimum of 5. It has increased from 0.77 (Mar 23) to 1.88, marking an increase of 1.11.
  • For Cash EPS (Rs.), as of Mar 24, the value is 2.54. This value is below the healthy minimum of 3. It has increased from 1.30 (Mar 23) to 2.54, marking an increase of 1.24.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 16.58. It has increased from 14.72 (Mar 23) to 16.58, marking an increase of 1.86.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 16.58. It has increased from 14.72 (Mar 23) to 16.58, marking an increase of 1.86.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 33.07. It has increased from 27.73 (Mar 23) to 33.07, marking an increase of 5.34.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 3.38. This value is within the healthy range. It has increased from 1.68 (Mar 23) to 3.38, marking an increase of 1.70.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 2.72. This value is within the healthy range. It has increased from 1.13 (Mar 23) to 2.72, marking an increase of 1.59.
  • For PBT / Share (Rs.), as of Mar 24, the value is 2.65. This value is within the healthy range. It has increased from 1.09 (Mar 23) to 2.65, marking an increase of 1.56.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 1.89. This value is below the healthy minimum of 2. It has increased from 0.75 (Mar 23) to 1.89, marking an increase of 1.14.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 1.88. This value is below the healthy minimum of 2. It has increased from 0.75 (Mar 23) to 1.88, marking an increase of 1.13.
  • For PBDIT Margin (%), as of Mar 24, the value is 10.21. This value is within the healthy range. It has increased from 6.04 (Mar 23) to 10.21, marking an increase of 4.17.
  • For PBIT Margin (%), as of Mar 24, the value is 8.23. This value is below the healthy minimum of 10. It has increased from 4.07 (Mar 23) to 8.23, marking an increase of 4.16.
  • For PBT Margin (%), as of Mar 24, the value is 8.01. This value is below the healthy minimum of 10. It has increased from 3.93 (Mar 23) to 8.01, marking an increase of 4.08.
  • For Net Profit Margin (%), as of Mar 24, the value is 5.71. This value is within the healthy range. It has increased from 2.72 (Mar 23) to 5.71, marking an increase of 2.99.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 5.68. This value is below the healthy minimum of 8. It has increased from 2.72 (Mar 23) to 5.68, marking an increase of 2.96.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 11.34. This value is below the healthy minimum of 15. It has increased from 5.13 (Mar 23) to 11.34, marking an increase of 6.21.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 15.61. This value is within the healthy range. It has increased from 7.31 (Mar 23) to 15.61, marking an increase of 8.30.
  • For Return On Assets (%), as of Mar 24, the value is 7.43. This value is within the healthy range. It has increased from 3.48 (Mar 23) to 7.43, marking an increase of 3.95.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.03. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 0.03.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 1.41. It has increased from 1.30 (Mar 23) to 1.41, marking an increase of 0.11.
  • For Current Ratio (X), as of Mar 24, the value is 2.21. This value is within the healthy range. It has decreased from 2.35 (Mar 23) to 2.21, marking a decrease of 0.14.
  • For Quick Ratio (X), as of Mar 24, the value is 1.59. This value is within the healthy range. It has decreased from 1.64 (Mar 23) to 1.59, marking a decrease of 0.05.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 3.70. This value is below the healthy minimum of 4. It has increased from 3.10 (Mar 23) to 3.70, marking an increase of 0.60.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 46.52. This value is within the healthy range. It has increased from 43.25 (Mar 23) to 46.52, marking an increase of 3.27.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 27.04. This value is within the healthy range. It has increased from 20.53 (Mar 23) to 27.04, marking an increase of 6.51.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 2,126.72. It has increased from 1,280.99 (Mar 23) to 2,126.72, marking an increase of 845.73.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.26. This value is within the healthy range. It has increased from 0.90 (Mar 23) to 1.26, marking an increase of 0.36.
  • For EV / EBITDA (X), as of Mar 24, the value is 12.32. This value is within the healthy range. It has decreased from 14.95 (Mar 23) to 12.32, marking a decrease of 2.63.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.27. This value is within the healthy range. It has increased from 0.92 (Mar 23) to 1.27, marking an increase of 0.35.
  • For Price / BV (X), as of Mar 24, the value is 2.54. This value is within the healthy range. It has increased from 1.74 (Mar 23) to 2.54, marking an increase of 0.80.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.27. This value is within the healthy range. It has increased from 0.92 (Mar 23) to 1.27, marking an increase of 0.35.
  • For EarningsYield, as of Mar 24, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 23) to 0.04, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Morepen Laboratories Ltd as of March 12, 2025 is: ₹42.94

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Morepen Laboratories Ltd is Overvalued by 13.60% compared to the current share price 49.70

Intrinsic Value of Morepen Laboratories Ltd as of March 12, 2025 is: 43.82

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Morepen Laboratories Ltd is Overvalued by 11.83% compared to the current share price 49.70

Last 5 Year EPS CAGR: 2.04%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock is trading at a low valuation with an average P/B ratio of 1.90 and average Dividend Yield of 6.65%.
  2. The stock has a low average Working Capital Days of 3.00, which is a positive sign.
  3. The company has higher reserves (320.08 cr) compared to borrowings (116.85 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (339.08 cr) and profit (54.00 cr) over the years.
  1. The stock has a low average ROCE of 10.08%, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 16.25, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Morepen Laboratories Ltd:
    1. Net Profit Margin: 5.71%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 15.61% (Industry Average ROCE: 16%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 11.34% (Industry Average ROE: 16.32%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 27.04
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.59
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 21.6 (Industry average Stock P/E: 42.42)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.03
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Morepen Laboratories Ltd. is a Public Limited Listed company incorporated on 01/12/1984 and has its registered office in the State of Himachal Pradesh, India. Company's Corporate Identification Number(CIN) is L24231HP1984PLC006028 and registration number is 006028. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 1537.59 Cr. and Equity Capital is Rs. 102.23 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
PharmaceuticalsMorepen Village, Solan District Himachal Pradesh 173205investors@morepen.com
http://www.morepen.com
Management
NamePosition Held
Mr. Sushil SuriChairman & Managing Director
Mr. Sanjay SuriWhole Time Director
Mr. Sukhcharan SinghIndependent Director
Mr. Praveen Kumar DuttIndependent Director
Mr. Bhupender Raj WadhwaIndependent Director
Mrs. SavitaIndependent Director
Mr. Manoj JoshiIndependent Director
Mr. Ranjit KhattarIndependent Director
Mr. Sharad JainIndependent Director

FAQ

What is the latest intrinsic value of Morepen Laboratories Ltd?

The latest intrinsic value of Morepen Laboratories Ltd as on 11 March 2025 is ₹42.94, which is 13.60% lower than the current market price of 49.70, indicating the stock is overvalued by 13.60%. The intrinsic value of Morepen Laboratories Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹2,722 Cr. and recorded a high/low of ₹101/38.6 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹1,001 Cr and total liabilities of ₹1,562 Cr.

What is the Market Cap of Morepen Laboratories Ltd?

The Market Cap of Morepen Laboratories Ltd is 2,722 Cr..

What is the current Stock Price of Morepen Laboratories Ltd as on 11 March 2025?

The current stock price of Morepen Laboratories Ltd as on 11 March 2025 is ₹49.7.

What is the High / Low of Morepen Laboratories Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Morepen Laboratories Ltd stocks is ₹101/38.6.

What is the Stock P/E of Morepen Laboratories Ltd?

The Stock P/E of Morepen Laboratories Ltd is 21.6.

What is the Book Value of Morepen Laboratories Ltd?

The Book Value of Morepen Laboratories Ltd is 20.3.

What is the Dividend Yield of Morepen Laboratories Ltd?

The Dividend Yield of Morepen Laboratories Ltd is 0.00 %.

What is the ROCE of Morepen Laboratories Ltd?

The ROCE of Morepen Laboratories Ltd is 16.8 %.

What is the ROE of Morepen Laboratories Ltd?

The ROE of Morepen Laboratories Ltd is 12.0 %.

What is the Face Value of Morepen Laboratories Ltd?

The Face Value of Morepen Laboratories Ltd is 2.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Morepen Laboratories Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE